How Will Loss of Exclusivity Affect Drug Prices?

Ten drugs are expected to lose their exclusivity this year, including Roche’s Lucentis for macular degeneration. Other companies, such as AbbVie and Pfizer, are also expected to face loss of exclusivity for some of their products. In coming years, more drugs are expected to face competition, including Abbvie’s highly profitable Humira drug in 2023.

“As drugmakers respond to the COVID-19 pandemic by developing vaccines and therapeutics, many of them are losing patent protection on older—and once lucrative—medicines. Each year, many of the pharmaceutical industry’s stalwart products lose their exclusive hold on the market, offering an opportunity for generics makers to seize share with cheaper copycats.” Read more here.

(Source: Eric Sagonowsky, Fierce Pharma, 3/9/21)